Download PDF
Planta Med 2011; 77(14): 1569-1574
DOI: 10.1055/s-0030-1270956
Biological and Pharmacological Activity
Original Papers
© Georg Thieme Verlag KG Stuttgart · New York

The 2′,4′,6′-Trihydroxyacetophenone Isolated from Myrcia multiflora Has Antiobesity and Mixed Hypolipidemic Effects with the Reduction of Lipid Intestinal Absorption

Eduardo Antonio Ferreira1 , Eliana Fortes Gris1 , Jussara Matos Rebello1 , João Francisco Gomes Correia1 , Luis Flávio Souza de Oliveira1 , Danilo Wilhelm Filho2 , Rozangela Curi Pedrosa1
  • 1Department of Biochemistry, CCB, Federal University of Santa Catarina, Florianópolis, SC, Brazil
  • 2Department of Ecology and Zoology, CCB, Federal University of Santa Catarina, Florianópolis, SC, Brazil
Further Information

Publication History

received July 8, 2010 revised February 10, 2011

accepted March 9, 2011

Publication Date:
06 April 2011 (online)

    Permissions and Reprints

Abstract

This study evaluated the hypolipidemic and antiobesity effects of phloroacetophenone (2′,4′,6′-trihydroxyacetophenone, THA) isolated from Myrcia multiflora and their relationship with triglyceride (TG) intestinal absorption and pancreatic lipase activity inhibition. The hypolipidemic effect of THA was evaluated by acute (Triton WR-1339 treatment) and chronic assay (high-fat diet treatment), the antiobesity effect was evaluated by chronic assay (high-fat diet treatment), while the inhibition of enzymatic activity of pancreatic lipase was measured in the intestinal tissue of mice treated with high olive oil concentration. In the acute assay, THA caused greater total cholesterol (37 %) and triglyceride (46 %) serum level reduction than lovastatin (32 and 1 %), a HMG‐CoA reductase inhibitor or orlistat (26 and 34 %), a gastrointestinal lipase inhibitor. In addition, in the chronic assay with a high-fat diet, THA reduced cholesterol and triglyceride levels (32 and 61 %, respectively) while lovastatin showed a decrease of 35 and 49 %, respectively. THA also caused a reduction in weight gain very similar to orlistat (40 and 38 %, respectively) when the animals were submitted to a high-fat diet. Moreover, THA showed a stronger and continuous pancreatic lipase inhibitory activity when compared with orlistat, causing inhibition of this enzyme during 6 hours associated to a significant reduction of triglyceride serum levels. The in vivo antiobesity and hypolipidemic effects of THA may be partly mediated by delaying the intestinal absorption of dietary fat by inhibiting pancreatic lipase activity.

Key words

antiobesity effect - mixed hypolipidemic activity - Myrcia multiflora - Myrtaceae - pancreatic lipase inhibitor - 2′,4′,6′‐trihydroxyacetophenone

References

  • 1 Friedman J M. Obesity: Causes and control of excess body fat.  Nature. 2009;  459 340-342
    CrossrefPubMedGoogle Scholar
  • 2 World Health Organization (WHO) .Fact sheet: obesity and overweight. http://www.who.int/mediacentre/factsheets/fs311/en/print.html Accessed May 9, 2009
    Google Scholar
  • 3 Weaver J U. Classical endocrine diseases causing obesity.  Front Horm Res. 2008;  36 212-228
    PubMedGoogle Scholar
  • 4 Ofir D, Laveneziana P, Webb K A, O'Donnell D E. Ventilatory and perceptual responses to cycle exercise in obese women.  J Appl Physiol. 2007;  102 2217-2226
    CrossrefPubMedGoogle Scholar
  • 5 Sørensen T I, Virtue S, Vidal-Puig A. Obesity as a clinical and public health problem: Is there a need for a new definition based on lipotoxicity effects?.  Biochim Biophys Acta. 2010;  1801 400-404
    CrossrefPubMedGoogle Scholar
  • 6 Eckel R H. Clinical practice. Nonsurgical management of obesity in adults.  N Engl J Med. 2008;  358 1941-1950
    CrossrefPubMedGoogle Scholar
  • 7 Flegal K M, Graubard B I, Williamson D F, Gail M H. Cause-specific excess deaths associated with underweight, overweight, and obesity.  JAMA. 2007;  298 2028-2037
    CrossrefPubMedGoogle Scholar
  • 8 Marinou K, Tousoulis D, Antonopoulos A S, Stefanadi E, Stefanadis C. Obesity and cardiovascular disease: from pathophysiology to risk stratification.  Int J Cardiol. 2010;  138 3-8
    CrossrefPubMedGoogle Scholar
  • 9 Friedman J M. A war on obesity, not the obese.  Science. 2003;  299 856-858
    CrossrefPubMedGoogle Scholar
  • 10 Lenz M, Richter T, Mühlhauser I. The morbidity and mortality associated with overweight and obesity in adulthood: a systematic review.  Dtsch Arztebl Int. 2009;  106 641-648
    CrossrefPubMedGoogle Scholar
  • 11 Woo M N, Bok S H, Lee M K, Kim H J, Jeon S M, Do G M, Shin S K, Ha T Y, Choi M S. Anti-obesity and hypolipidemic effects of a proprietary herb and fiber combination (S & S PWH) in rats fed high-fat diets.  J Med Food. 2008;  11 169-178
    CrossrefPubMedGoogle Scholar
  • 12 Bamba V, Rader D J. Obesity and atherogenic dyslipidemia.  J Gastrol. 2007;  132 2181-2190
    PubMedGoogle Scholar
  • 13 Kuo D H, Yeh C H, Shieh P C, Cheng K C, Chen F A, Cheng J T. Effect of shanzha, a Chinese herbal product, on obesity and dyslipidemia in hamsters receiving high-fat diet.  J Ethnopharmacol. 2009;  124 544-550
    CrossrefPubMedGoogle Scholar
  • 14 Zalesin K C, Franklin B A, Miller W M, Peterson E D, McCullough P A. Impact of obesity on cardiovascular disease.  Endocrinol Metab Clin N Am. 2008;  37 663-684
    CrossrefPubMedGoogle Scholar
  • 15 Lee K R, Hong S W, Kwak J H, Pyo S, Jee O P. Phenolic constituents from the aerial parts of Artemisia stolonifera.  Arch Pharm Res. 1996;  19 231-234
    CrossrefPubMedGoogle Scholar
  • 16 Chosson E, Chaboud A, Chulia A J, Raynaud J. A phloroacetophenone glucoside from Rhododendron ferrugineum.  Phytochemistry. 1998;  47 87-88
    CrossrefPubMedGoogle Scholar
  • 17 Dai Y, He X J, Zhou G X, Kurihara H, Ye W C, Yao X S. Acylphloroglucinol glycosides from the fruits of Pyracantha fortuneana.  J Asian Nat Prod Res. 2008;  10 111-117
    CrossrefPubMedGoogle Scholar
  • 18 Yoshikawa M, Shimada H, Nishida N, Li Y, Toguchida I, Yamahara J, Matsuda H. Antidiabetic principles of natural medicines. II. Aldose reductase and alpha-glucosidase inhibitors from Brazilian natural medicine, the leaves of Myrcia multiflora DC. (Myrtaceae): structures of myrciacitrins I and II and myrciaphenones A and B.  Chem Pharm Bull. 1998;  46 113-119
    CrossrefPubMedGoogle Scholar
  • 19 Matsuda H, Nishida N, Yoshikawa M. Antidiabetic principles of natural medicines. V. Aldose reductase inhibitors from Myrcia multiflora DC. (2): Structures of myrciacitrins III, IV, and V.  Chem Pharm Bull. 2002;  50 429-431
    CrossrefPubMedGoogle Scholar
  • 20 Suksamrarn A, Eiamong S, Piyachaturawat P, Byrne L T. A phloracetophenone glucoside with choleretic activity from Curcuma comosa.  Phytochemistry. 1997;  45 103-105
    CrossrefPubMedGoogle Scholar
  • 21 Brandão M G L, Nery C G C, Mamão M A S, Krettli A U. Two methoxylated flavone glycosides from Bidens pilosa.  Phytochemistry. 1998;  48 397-399
    CrossrefPubMedGoogle Scholar
  • 22 Zhao L M, Jin H S, Sun L P, Piao H R, Quan Z S. Synthesis and evaluation of antiplatelet activity of trihydroxychalcone derivatives.  Bioorg Med Chem Lett. 2005;  15 5027-5029
    CrossrefPubMedGoogle Scholar
  • 23 Vásquez-Freire M J, Lamela M, Calleja J M. Hypolipidaemic activity of a polysaccharide extract from Fucus vesiculosus L.  Phytother Res. 1996;  10 647-650
    CrossrefPubMedGoogle Scholar
  • 24 Allain C C, Poon L C, Chan C S G, Richmond W, Fu P C. Enzymatic determination of total serum cholesterol.  Clin Chem. 1974;  20 470-475
    PubMedGoogle Scholar
  • 25 McGowan M W, Artiss J D, Strandbergh D R, Zak B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides.  Clin Chem. 1983;  29 538-542
    PubMedGoogle Scholar
  • 26 Kurooka S, Okamoto S, Hashimoto M. A novel and simple colorimetric assay for human serum lipase.  J Biochem. 1977;  81 361-369
    PubMedGoogle Scholar
  • 27 Harborne J B. Phenolic compounds. Harborne JB Phytochemical methods: a guide to modern techniques of plant analysis, 3rd edition. London; Chapman & Hall 1998: 40-106
    Google Scholar
  • 28 Piyachaturawat P, Suwanampai P, Komaratat P, Chuncharunee A, Suksamrarn A. Effect of phloracetophenone on bile flow and biliary lipids in rats.  Hepatol Res. 1998;  12 198-206
    CrossrefPubMedGoogle Scholar
  • 29 Piyachaturawat P, Chai-ngam N, Chuncharunee A, Komaratat P, Suksamrarn A. Choleretic activity of phloracetophenone in rats: structure-function studies using acetophenone analogues.  Eur J Pharmacol. 2000;  387 221-227
    CrossrefPubMedGoogle Scholar
  • 30 Piyachaturawat P, Tubtim C, Chuncharunee A, Komaratat P, Suksamrarn A. Evaluation of the acute and subacute toxicity of a choleretic phloracetophenone in experimental animals.  Toxicol Lett. 2002;  129 123-132
    CrossrefPubMedGoogle Scholar
  • 31 Piyachaturawat P, Srivoraphan P, Chuncharunee A, Komaratat P, Suksamrarn A. Cholesterol lowering effects of a choleretic phloracetophenone in hypercholesterolemic hamsters.  Eur J Pharmacol. 2002;  439 141-147
    CrossrefPubMedGoogle Scholar
  • 32 Ito H, Nakasuga K, Ohshima A, Sakai Y, Maruyama T, Kaji Y, Harada M, Jingu S, Sakamoto M. Excess accumulation of body fat is related to dyslipidemia in normal-weight subjects.  Int J Obes Relat Metab Disord. 2004;  28 242-247
    PubMedGoogle Scholar
  • 33 MacBride P. Triglycerides and risk for coronary artery disease.  Curr Atheroscler Rep. 2008;  10 386-390
    CrossrefPubMedGoogle Scholar
  • 34 Garattini S, Paoletti R. Drugs affecting lipid metabolism. Amsterdam; Elsevier 1961: 144
    Google Scholar
  • 35 Pedrosa R C, Meyre-Silva C, Cechinel-Filho V, Benassi J C, Oliveira L F S, Zancanaro V, Dal Magro J, Yunes R A. Hypolipidaemic activity of methanol extract of Aleurites moluccana.  Phytother Res. 2002;  16 765-768
    CrossrefPubMedGoogle Scholar
  • 36 Amrani S, Harnafi H, Bouanani N E H, Aziz M, Caid H S, Manfredini S, Besco E, Napolitano M, Bravo E. Hypolipidaemic activity of aqueous Ocimum basilicum extract in acute hyperlipidaemia induced by triton WR-1339 in rats and its antioxidant property.  Phytother Res. 2006;  20 1040-1045
    CrossrefPubMedGoogle Scholar
  • 37 Ueshima K, Akihisa-Umeno H, Nagayoshi A, Takakura S, Matsuo M, Mutoh S. A gastrointestinal lipase inhibitor reduces progression of atherosclerosis in mice fed a western-type diet.  Eur J Pharmacol. 2004;  501 137-142
    CrossrefPubMedGoogle Scholar
  • 38 Martins F, Noso T M, Porto V B, Curiel A, Gambero A, Bastos D H M, Ribeiro M L, Carvalho P O. Maté tea inhibits in vitro pancreatic lipase activity and has hypolipidemic effect on high-fat-diet-induced obese mice.  Obesity. 2010;  18 42-47
    CrossrefPubMedGoogle Scholar
  • 39 Schieffer B, Drexler H. Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases.  Am J Cardiol. 2003;  91 12H-18H
    PubMedGoogle Scholar
  • 40 Schiavo M, Lunardelli A, Oliveira J R. Influência da dieta na concentração sérica de triglicerídeos.  J Bras Patol Med Lab. 2003;  39 283-288
    CrossrefPubMedGoogle Scholar
  • 41 McNeely W, Benfield P. Orlistat.  Drugs. 1998;  56 241-249
    CrossrefPubMedGoogle Scholar
  • 42 Ballinger A, Peikin S R. Orlistat: its current status as an antiobesity drug.  Eur J Pharmacol. 2002;  440 109-117
    CrossrefPubMedGoogle Scholar
  • 43 Reitsma J B, Cabezas M C, de Bruin T W, Erkelens D W. Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor.  Metabolism. 1994;  43 293-298
    CrossrefPubMedGoogle Scholar
  • 44 Ellrichmann M, Kapelle M, Ritter P R, Holst J J, Herzig K H, Schmidt W E, Schmitz F, Meier J J. Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations.  J Clin Endocrinol Metab. 2008;  93 3995-3998
    CrossrefPubMedGoogle Scholar
  • 45 Hsieh C J, Wang P W, Liu R T, Tung S C, Chien W Y, Chen J F, Chen C H, Kuo M C, Hu Y H. Orlistat for obesity: benefits beyond weight loss.  Diabetes Res Clin Pract. 2005;  67 78-83
    CrossrefPubMedGoogle Scholar
  • 46 Birari R B, Bhutani K K. Pancreatic lipase inhibitors from natural sources: unexplored potential.  Drug Discov Today. 2007;  12 879-889
    CrossrefPubMedGoogle Scholar

Rozangela Curi Pedrosa

Departamento de Bioquímica
Centro de Ciências Biológicas
Universidade Federal de Santa Catarina, Campus Trindade

88040-900 Florianópolis – SC

Brazil

Phone: +55 48 37 21 50 48

Fax: +55 48 37 21 96 72

Email: roza@ccb.ufsc.br

    www.thieme-connect.de/ejournals/toc/plantamedica
>